IP Library Granted Patent US 8,541,614
Granted Patent B2
US 8,541,614 · App. 12/417,671 · Granted Sep 24, 2013

Process for the preparation of (−)-(4-chloro-phenyl)-(3-trifluoromethyl-phenoxy)-acetic acid 2-acetylamino-ethyl ester

Inventors: Diego Broggini (Armin-Bollinger-weg, CH); Hartmut Burghard Zinser (J. J. Wepferstrasse, CH)
Assignee: Metabolex, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,541,614
App. No.
12/417,671
Granted
Sep 24, 2013
Kind
B2
Abstract

The present invention is directed to a novel process for the preparation of (4-chloro-phenyl)-(3-trifluoromethyl-phenoxy)-acetic acid 2-acetylamino-ethyl ester, useful in the treatment of metabolic disorders and further to a process for the preparation of (4-chloro-phenyl)-(3-trifluoromethyl-phenoxy)-acetic acid, a synthesis intermediate.

Claims (38)

1. A process for preparing the compound of formula (I):

comprising:

(a) reacting the compound of formula (IX-R):

with an acid at a temperature of from about 70° C. to about 150° C. to yield the compound of formula (II):

having an enantiomeric excess of about 99% or greater;

(b) reacting the compound of formula (II) with a source of chlorine, neat or in an organic solvent, to yield the compound of formula (X):

(c) reacting the compound of formula (X) with a compound of formula (XI):

neat or in an organic solvent, to yield the compound of formula (I).

2. The process of claim 1 further comprising preparing the compound of formula (IX-R) by reacting the compound of formula (VII):

with a salt of the compound of formula (VIII):

in the presence of a second catalyst, in an organic solvent or mixture thereof to yield the compound of formula (IX-R).

3. The process of claim 2 further comprising preparing the compound of formula (VII) by reacting the compound of formula (V):

with a compound of formula (VI):

in the presence of a first catalyst and a coupling agent, in an aprotic organic solvent or mixture thereof, to yield the compound of formula (VII).

4. The process of claim 1 where the source of chlorine is thionyl chloride.

5. The process of claim 4 where the thionyl chloride is present in an amount in the range of from about 1.2 to about 2.5 molar equivalents with respect to the compound of formula (II).

6. The process of claim 5 where the thionyl chloride is present in an amount of about 1.4 molar equivalents with respect to the compound of formula (II).

7. The process of claim 1 where the compound of formula (XI) is present in an amount in the range of from about 1.0 to about 3.0 molar equivalents with respect to the compound of formula (X).

8. The process of claim 7 where the compound of formula (XI) is present in an amount of about 1.4 molar equivalents with respect to the compound of formula (X).

9. The process of claim 1 where step (b) is carried out in dimethylacetamide.

10. The process of claim 1 where step (b) is carried out at a temperature of about 80° C.

11. The process of claim 1 where step (c) is carried out in dimethylacetamide.

12. The process of claim 1 where step (c) is carried out at a temperature of about 20° C.

13. The process of claim 1 where the acid of step (a) is selected from the group consisting of concentrated HCl, HBr, H 2 SO 4 and methanesulfonic acid.

14. The process of claim 13 where the acid is concentrated HCl.

15. The process of claim 1 where the compound of formula (IX-R) is reacted with the acid neat.

16. The process of claim 1 where the compound of formula (IX-R) is reacted with the acid at a temperature of about 80° C.

17. The process of claim 1 , further comprising crystallizing the compound of formula (II) from a mixture of toluene and petrol ether.

18. The process of claim 2 where the salt of the compound of formula (VIII) is the salt formed with LiOH*H 2 O.

19. The process of claim 18 where the salt of the compound of formula (VIII) is present in an amount in the range of from about 1.0 to about 3.0 molar equivalents with respect to the compound of formula (VII).

20. The process of claim 19 where the salt of the compound of formula (VIII) is present in about 1.2 molar equivalents with respect to the compound of formula (VII).

21. The process of claim 2 where the second catalyst is NaI.

22. The process of claim 2 where the compound of formula (VII) is reacted with the salt of the compound of formula (VIII) in THF.

23. The process of claim 2 where the compound of formula (VII) is reacted with the salt of the compound of formula (VIII) at about −5° C.

24. The process of claim 3 where the compound of formula (VI) is present in an amount in the range of from about 1.0 to about 1.5 molar equivalents with respect to the compound of formula (V).

25. The process of claim 3 where the first catalyst is dimethylaminopyridine and the coupling agent is dicyclohexylcarbodiimide.

26. The process of claim 3 where the aprotic solvent is toluene.

27. The process of claim 3 where the compound of formula (V) is reacted with the compound of formula (VI) at a temperature in the range of from about −10° C. to about 30° C.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2016
From: CYMABAY THERAPEUTICS, INC.
To: DIATEX, INC.
Reel/Frame 039045/0152 →
RELEASE OF SECURITY INTEREST Recorded Aug 7, 2015
From: SILICON VALLEY BANK; OXFORD FINANCE LLC
To: CYMABAY THERAPEUTICS, INC.
Reel/Frame 036307/0406 →
SECURITY AGREEMENT Recorded Nov 22, 2013
From: CYMABAY THERAPEUTICS, INC.
To: SILICON VALLEY BANK; OXFORD FINANCE LLC
Reel/Frame 031710/0508 →
CHANGE OF NAME Recorded Oct 30, 2013
From: METABOLEX, INC.
To: CYMABAY THERAPEUTICS, INC.
Reel/Frame 031517/0181 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2011
From: JANSSEN PHARMACEUTICA N.V
To: METABOLEX, INC.
Reel/Frame 026988/0926 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 3, 2009
From: BROGGINI, DIEGO; ZINSER, HARMUT
To: JANSSEN PHARMACEUTIC N.V.
Reel/Frame 022500/0762 →
Continuity (2)
Provisional Application 61042078 · Apr 3, 2008
Related Publication 20100093854A1 · Apr 15, 2010